TQB2825 for lymphoma that has returned or not responded
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new investigational drug called TQB2825, given as a shot under the skin, for people with certain types of lymphoma that have not responded to previous CD20-targeted treatments. The goal is to see if the drug is safe and effective, and it might help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old.
- You have a blood cancer called lymphoma (like diffuse large B-cell, follicular, mantle cell, or marginal zone lymphoma) that is CD20-positive.
- You have already tried at least one treatment that targets CD20 (such as rituximab), and your cancer didn't improve, got worse, or came back.
- You have at least one tumor that can be measured on a scan (lymph node larger than 1.5 cm or outside the lymph nodes larger than 1 cm).
- Your blood counts and liver/kidney function meet minimum levels (your doctor will check this).
- You are not pregnant and agree to use effective birth control during and for 12 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection (TQB2825) against standard immunotherapy for people with follicular lymphoma that has come back or hasn't responded to at least two previous treatments. The goal is to see if it can help control the cancer and improve outcomes.
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
This trial tests a new tablet (TQB3702) combined with standard immune-and-chemo therapy for certain types of B-cell lymphoma that have come back or not responded to previous treatment. It aims to see if the combination is safe and effective.
This study tests an investigational drug called TQB2922, given as an injection under the skin, for people with advanced non-small cell lung cancer that has not improved with standard treatments. The goal is to see if the drug is safe and helpful.
This study tests a new injection called TQB2930 designed to treat advanced solid cancers (cancers that have spread) that have HER2 protein on their surface. The goal is to see if this treatment can shrink these tumors and help patients live longer.
This trial tests a new injectable drug called TQB2934 for people with systemic light chain amyloidosis. It aims to see if the drug is safe and effective for those whose disease has come back or gotten worse after previous treatment.
Hear when a new CD20-positive Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.